Regulations.gov document
Attachment 2 Approved labelling for NEURONTIN Tablets re Suitability Petition from Strides…
Supporting & Related Material · FDA-2023-P-4876 · posted Nov 3, 2023
Key facts
| Document ID | FDA-2023-P-4876-0004 |
|---|---|
| Title | Attachment 2 Approved labelling for NEURONTIN Tablets re Suitability Petition from Strides Pharma Inc. |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2023-P-4876 |
| Posted | Nov 3, 2023 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: